1. Automated insulin delivery (AID) significantly reduced glycated hemoglobin levels in a 13-week trial.
2. AID resulted in reduced mean glycated hemoglobin (HbA1c) level and increased time in target glucose range.
3. AID remained in automated mode for a median of 93% of the time.
4. AID was effective across diverse patient demographics, including those new to using insulin pumps.
5. Further studies are needed to evaluate long-term outcomes.

Source: The New England Journal of Medicine